Kwok Chun T, Morris Alex, de Belleroche Jacqueline S
Neurogenetics Group, Division of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK.
Eur J Hum Genet. 2014 Apr;22(4):492-6. doi: 10.1038/ejhg.2013.184. Epub 2013 Aug 14.
Mutations in the SQSTM1 gene have been reported to be associated with amyotrophic lateral sclerosis (ALS). We sought to determine the frequency of these mutations in a UK familial ALS (FALS) cohort. Sequences of all eight exons of the SQSTM1 gene were analysed in index cases from 61 different FALS kindred lacking known FALS mutations. Six exonic variants c.463G>A, p.(Glu155Lys), c.822G>C, p.(Glu274Asp), c.888G>T, p.(=), c.954C>T, p.(=), c.1038G>A, p.(=) and c.1175C>T, p.(Pro392Leu) were identified in five FALS index cases, three of which were non-synonymous and three were synonymous. One index case harboured three variants (c.822G>C, c.888G>T and c.954C>T), and a second index case harboured two variants (c.822G>C and c.954C>T). Only the p.(Pro392Leu) and p.(Glu155Lys) mutations were predicted to be pathogenic. In one p.(Pro392Leu) kindred, the carrier developed both ALS and Paget's disease of bone (PDB), and, in the p.(Glu155Lys) kindred, the father of the proband developed PDB. All p.(Pro392Leu) carriers were heterozygous for a previously reported founder haplotype for PDB, where this mutation has an established causal effect. The frequency of the p.(Pro392Leu) mutation in this UK FALS cohort was 2.3% and 0.97% overall including three previously screened FALS cohorts. Our results confirm the presence of the p.(Pro392Leu) SQSTM1 mutation in FALS. This mutation is the most common SQSTM1 mutation found in ALS to date, and a likely pathogenicity is supported by having an established causal role in PDB. The occurrence of the same mutation in ALS and PDB is indicative of a common pathogenic pathway that converges on protein homeostasis.
据报道,SQSTM1基因突变与肌萎缩侧索硬化症(ALS)有关。我们试图确定这些突变在英国家族性ALS(FALS)队列中的频率。对61个不同的FALS家族中缺乏已知FALS突变的先证者进行了SQSTM1基因所有8个外显子的序列分析。在5例FALS先证者中鉴定出6个外显子变异,分别为c.463G>A,p.(Glu155Lys);c.822G>C,p.(Glu274Asp);c.888G>T,p.(=);c.954C>T,p.(=);c.1038G>A,p.(=)和c.1175C>T,p.(Pro392Leu),其中3个为非同义突变,3个为同义突变。1例先证者携带3个变异(c.822G>C、c.888G>T和c.954C>T),另1例先证者携带2个变异(c.822G>C和c.954C>T)。只有p.(Pro392Leu)和p.(Glu155Lys)突变被预测具有致病性。在1个p.(Pro392Leu)家族中,携带者同时患ALS和骨佩吉特病(PDB),在p.(Glu155Lys)家族中,先证者的父亲患PDB。所有p.(Pro392Leu)携带者均为先前报道的PDB奠基者单倍型的杂合子,该突变具有既定的因果效应。在这个英国FALS队列中,p.(Pro392Leu)突变的频率为2.3%,包括3个先前筛查的FALS队列在内,总体频率为0.97%。我们的结果证实了FALS中存在p.(Pro392Leu) SQSTM1突变。该突变是迄今为止在ALS中发现的最常见的SQSTM1突变,并且在PDB中具有既定的因果作用,这支持了其可能的致病性。ALS和PDB中出现相同的突变表明存在一条汇聚于蛋白质稳态的共同致病途径。